Former Novartis executive director heads up new immuno-oncology play

Catherine Sabatos-Peyton’s last startup was only in operation for about a year before Novartis AG scooped it up for a cool $248 million. Now, after about five years continuing the work of that startup — cancer firm CoStim Pharmaceuticals — inside of Novartis, including as executive director and head of immune modulation, Sabatos-Peyton is striking out on her own again.